Recruiting
Phase 1
Phase 2

RR-HNK

Sponsor:

Carolyn Rodriguez

Code:

NCT06575075

Conditions

Obsessive-Compulsive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

RR-HNK/Hydroxynorketamine

Placebo

Study Details

Brief summary:

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Conditions

Obsessive-Compulsive Disorder

Study ID

NCT06575075

Start date

Jan 23, 2026

Status verified date

Aug, 2026

Completion date

Nov 30, 2029

Anticipated

Primary completion date

Nov 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ages 18-65
  • Meet the criteria for OCD diagnosis
  • Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
  • Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
  • Able to provide informed consent

Exclusion Criteria:

  • Allergy or hypersensitivity to ketamine
  • Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
  • Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
  • Lifetime history of deep brain stimulation

Study Design

Enrollment

45 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 0.25 mg/kg RR-HNK

OCD patients in this arm will receive 0.25mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.

experimental: 0.5 mg/kg RR-HNK

OCD patients in this arm will receive 0.5mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.

placebo comparator: Placebo (Sterile Saline)

OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.

Interventions

RR-HNK/Hydroxynorketamine

(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

Placebo

Sterile Saline

Primary outcome measure

  • Change in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) [ Time Frame: Baseline (Visit 3) to Week 1 (Visit 8), up to 1 week ]

Central Contacts and Locations

Central contacts

Alessa Gaeta, BA

650-723-4095ocdresearch@stanford.edu

Locations

Stanford University School of Medicine

Recruiting

Palo Alto, California, United States, 94305

More Information

Sponsor

Carolyn Rodriguez

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Keywords

  • OCD
  • AMPA receptor antagonist
  • hydroxynorketamine
  • ketamine metabolite

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Carolyn Rodriguez on 2026-08-12.